Status:
COMPLETED
A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis
Lead Sponsor:
Centocor, Inc.
Conditions:
Psoriasis
Parapsoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of the study is to evaluate the safety and effectiveness of scheduled and as needed treatment of psoriasis with infliximab. Infliximab (Remicade) targets specific proteins in the body's im...
Detailed Description
This is a phase III, multicenter, randomized (patients are assigned different treatments based on chance), double-blind (neither the patient nor the physician knows whether drug or placebo is being ta...
Eligibility Criteria
Inclusion
- Patients with diagnosis of plaque-type psoriasis for at least 6 months
- Patients with plaque-type psoriasis covering at least 10% of the body
Exclusion
- Patients with nonplaque forms of psoriasis
- Patients who have current drug-induced psoriasis
- Patients who are pregnant, nursing, or planning pregnancy (both men and women) within 18 months of enrollment
- Patients who had any previous treatment with infliximab or any therapeutic agent targeted at reducing tumor necrosis factor
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2005
Estimated Enrollment :
683 Patients enrolled
Trial Details
Trial ID
NCT00106847
Start Date
January 1 2003
End Date
July 1 2005
Last Update
May 17 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.